

Bio-Link Licensing Portfolio Q3 2018

	Program	Indication	Modality	Mechanism of Action	Owner	Discovery	Lead Generation	Pre-Clinical	Phase I	Phase II
Therapeutics	KT009	Chronic back pain	Growth factor	Regeneration of IVD tissue	Kunovus Technologies					
	Xanamem™	Alzheimer's disease	SM	Lowers CNS cortisol	Actinogen Medical					
	CNC332	Oncology	SM	Mitochondrial complex II inhibitor	Cancure					
	CNC225	Immuno-oncology	SM	Galectin inhibitor	Cancure					
	CD5-2	Immuno-oncology	Oligo nucleotide	Selective vascular endothelial-cadherin modulator	Centenary Institute & Mirrx Therapeutics					
	Dynamamin II inhibitor	Immuno-oncology	SM	Dynamamin II GTPase inhibitor	University of Queensland, CMRI, & University of Newcastle					
	Dynamamin I inhibitor	Refractory epilepsy	SM	Dynamamin I GTPase inhibitor	Children's Medical Research Institute & University of Newcastle					
	Deflexifol	Colorectal carcinoma / Solid tumours	5-FU / leucovorin formulation	Co-formulation to allow simultaneous dosing	FivepHusion					
	IK01400	Pain	Peptide	Targets PKG1-α	InterK Peptide Therapeutics					
	JCU303	Wound healing	Peptide	Accelerates wound closure & stimulates angiogenesis	James Cook University					
	Program	Technology			Owner	Prototype	Proof of Concept	Clinical Validation	Product Registration	
	EVestG™	Objective assessment of neurological diseases and optimisation of CNS drug trials			Neural Diagnostics					
	Program	Technology			Owner	Preclinical Proof of Concept		Clinical Proof of Concept		
Research Tools	GFP-tagged β-tubulin cell lines	Gene edited cell lines for cytoskeleton biology research and screening			Children's Cancer Institute					

LEGEND: SM: Small molecule; CMRI: Children's Medical Research Institute.